Opinion|Videos|November 12, 2024
New Data from AANEM 2024 in Generalized Myasthenia Gravis
Panelists discuss how recent data presented at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) conference may impact clinical practice for myasthenia gravis, highlighting emerging treatments they find particularly promising for future management of the condition.
Advertisement
Video content above is prompted by the following:
- Please share other interesting/practice-impacting data that were presented at AANEM 2024.
- What other emerging treatments are you excited about?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
- Setting Realistic Expectations for Antiamyloid Therapeutics
September 11th 2025
- Monitoring and Managing ARIA in Antiamyloid Treatments
September 10th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
10 Years of the Women Neurologists Group: A Preview of the 4th Annual Conference
3
NeurologyLive® Brain Games: September 14, 2025
4
This Week on NeurologyLive® — September 15, 2025
5